These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35123640)

  • 21. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
    Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
    Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.
    Zhao Y; Wu H; Shi J; Luo Y; Li X; Lan J; Ni W; Lu Y; Chen L; Tan Y; Lai X; Yu J; Huang H
    Am J Hematol; 2020 Sep; 95(9):1075-1084. PubMed ID: 32510625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.
    Pattipaka T; Sarp S; Nakhaei P; Güneş S
    Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
    Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
    Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.
    Tang Y; Yang D; Xie R; Zhong Z; You Y
    Transpl Immunol; 2023 Feb; 76():101743. PubMed ID: 36372140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency and Toxicity of Ruxolitinib as the Salvage Treatment in Steroid-Refractory Acute Graft-Versus-Host Disease after Haplo-Identical Stem Cell Transplantation.
    Liu Y; Fan Y; Zhang W; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Transplant Cell Ther; 2021 Apr; 27(4):332.e1-332.e8. PubMed ID: 33836880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice.
    Pan B; Shang L; Liu C; Gao J; Zhang F; Xu M; Li L; Sun Z; Li Z; Xu K
    Am J Transplant; 2021 Feb; 21(2):503-514. PubMed ID: 32805756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
    Kaurinovic M; Delli K; Jonk AE; Biswana A; Hazenberg CLE; Choi G; de Groot MR; Morsink LM; Vissink A; Bellido M
    Clin Oral Investig; 2022 May; 26(5):4209-4216. PubMed ID: 35169886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons.
    Tremblay G; Tomaras D; Strati E; Forsythe A
    J Health Econ Outcomes Res; 2021 Feb; 8(1):10-17. PubMed ID: 33768123
    [No Abstract]   [Full Text] [Related]  

  • 35. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
    Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38916740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
    Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
    Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
    Front Immunol; 2022; 13():954268. PubMed ID: 35990629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
    Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
    Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.
    Lu SY; Liu KY; Liu DH; Xu LP; Huang XJ
    Clin Exp Immunol; 2011 Aug; 165(2):264-77. PubMed ID: 21635226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.